Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Lebbé · SciRah

Researcher profile · Semantic Scholar

C. Lebbé

Share profile

C. Lebbé — researcher profile on SciRah

h-index: 92
Works: 712
Citations: 82K

Most-cited papers

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
C. Blank, M. Lucas, R. Scolyer, B. A. van de Wiel +64 more
2024New England Journal of Medicine448 citations Open access
Semantic Scholar
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022.
C. Garbe, T. Amaral, K. Peris, A. Hauschild +25 more
2022European Journal of Cancer315 citations Open access
Semantic Scholar
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.
C. Garbe, T. Amaral, K. Peris, A. Hauschild +25 more
2022European Journal of Cancer259 citations Open access
Semantic Scholar
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
P. Ascierto, M. Mandalà, P. Ferrucci, M. Guidoboni +26 more
2022Journal of Clinical Oncology200 citations Open access
Semantic Scholar
Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022.
Marie-Léa Gauci, C. Aristei, J. Becker, A. Blom +25 more
2022European Journal of Cancer150 citations Open access
Semantic Scholar
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023.
A. Stratigos, C. Garbe, C. Dessinioti, C. Lebbé +31 more
2023European Journal of Cancer122 citations Open access
Semantic Scholar
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023.
A. Stratigos, C. Garbe, C. Dessinioti, C. Lebbé +31 more
2023European Journal of Cancer93 citations Open access
Semantic Scholar
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
J. Chesney, I. Puzanov, F. Collichio, Parminder Singh +12 more
2023Journal for ImmunoTherapy of Cancer85 citations Open access
Semantic Scholar
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results
A. Diab, H. Gogas, S. Sandhu, G. Long +22 more
2023Journal of Clinical Oncology79 citations Open access
Semantic Scholar
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.
F. Dimitriou, K. Namikawa, I. Reijers, E. Buchbinder +42 more
2022Annals of Oncology65 citations Open access
Semantic Scholar
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
P. Bhave, T. Ahmed, S. Lo, A. Shoushtari +43 more
2022Journal for ImmunoTherapy of Cancer63 citations Open access
Semantic Scholar
Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy
L. Dousset, F. Poizeau, C. Robert, S. Mansard +24 more
2021JCO Precision Oncology56 citations Open access
Semantic Scholar
PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study.
J. Delyon, L. Biard, M. Renaud, M. Resche-Rigon +11 more
2022The Lancet Oncology47 citations Open access
Semantic Scholar
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
C. Garbe, R. Dummer, T. Amaral, R. Amaria +22 more
2023Nature Medicine39 citations Open access
Semantic Scholar
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study
F. De Braud, C. Dooms, R. Heist, C. Lebbé +25 more
2023Journal of Clinical Oncology38 citations Open access
Semantic Scholar
LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study
P. Ascierto, M. Mandalà, P. Ferrucci, P. Rutkowski +16 more
2021Annals of Oncology32 citations Open access
Semantic Scholar
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control study
L. Plaçais, S. Dalle, O. Dereure, S. Trabelsi +18 more
2022Annals of the Rheumatic Diseases31 citations Open access
Semantic Scholar
Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers—Emerging Strategies for Clinical Management
C. Ferrándiz-Pulido, Ulrike M. Leiter, C. Harwood, C. Proby +9 more
2023Transplantation30 citations Open access
Semantic Scholar
Endemic Kaposi’s Sarcoma
P. El Zeinaty, C. Lebbé, J. Delyon
2023Cancers30 citations Open access
Semantic Scholar
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.
M. Veron, S. Chevret, J. Grob, M. Beylot-Barry +21 more
2022European Journal of Cancer27 citations Open access
Semantic Scholar
IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy.
J. Delyon, C. Lebbé
2022Cancer Cell25 citations Open access
Semantic Scholar
The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review
V. Lancellotta, L. Del Regno, A. Di Stefani, B. Fionda +12 more
2022La radiologia medica24 citations Open access
Semantic Scholar
Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans
J. Beaziz, M. Battistella, J. Delyon, C. Farges +10 more
2021Cancers23 citations Open access
Semantic Scholar
Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years.
J. Blay, S. Piperno-Neumann, S. Watson, A. Dufresne +37 more
2023European Journal of Cancer22 citations Open access
Semantic Scholar
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401
R. Dummer, P. Corrie, R. Gutzmer, T. Meniawy +22 more
2023Journal of Clinical Oncology21 citations Open access
Semantic Scholar
Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation.
A. Weppler, L. Da Meda, I. Pires da Silva, Wen Xu +12 more
2023European Journal of Cancer21 citations
Semantic Scholar
Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients—The European MelSkinTox study
J. L'Orphelin, J. Cassecuel, L. Kandolf, C. Harwood +18 more
2023Journal of the European Academy of Dermatology and Venereology20 citations Open access
Semantic Scholar
Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study
F. Herms, B. Baroudjian, J. Delyon, P. Laly +3 more
2022Acta Dermato-Venereologica18 citations Open access
Semantic Scholar
Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma
R. Dummer, C. Robert, R. Scolyer, J. Taube +15 more
2023Cancer Research17 citations
Semantic Scholar
TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
J. Delyon, A. Vallet, Mélanie Bernard-Cacciarella, I. Kuzniak +6 more
2023Cancers16 citations Open access
Semantic Scholar
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
I. Pires da Silva, D. Zakria, T. Ahmed, Claudia Trojanello +13 more
2022Journal for ImmunoTherapy of Cancer16 citations Open access
Semantic Scholar
Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells
Marianne Gazzano, C. Parizot, D. Psimaras, A. Vozy +18 more
2022Frontiers in Immunology16 citations Open access
Semantic Scholar
Characteristics of circulating KSHV-infected viroblasts during active KSHV+ multicentric Castleman disease
Grégoire Martin de Frémont, Anthony Vanjak, Z. Sbihi, Silène Knapp +20 more
2022Blood Advances15 citations Open access
Semantic Scholar
SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC)
Marie-Léa Gauci, C. Coutzac, R. Houot, A. Marabelle +1 more
2021European Journal of Cancer15 citations Open access
Semantic Scholar
RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted Therapy
A. Jebali, M. Battistella, C. Lebbé, N. Dumaz
2021Biomedicines15 citations Open access
Semantic Scholar
Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC
P. Kubicek, A. Le Cesne, C. Lervat, M. Toulmonde +46 more
2023BMC Cancer14 citations Open access
Semantic Scholar
Yield of FDG PET/CT for Defining the Extent of Disease in Patients with Kaposi Sarcoma
Louise Pesqué, J. Delyon, C. Lheure, B. Baroudjian +4 more
2022Cancers14 citations Open access
Semantic Scholar
785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)
A. Diab, H. Gogas, S. Sandhu, G. Long +16 more
2022Annals of Oncology13 citations Open access
Semantic Scholar
Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.
P. Saiag, C. Robert, J. Grob, L. Mortier +14 more
2021European Journal of Cancer13 citations Open access
Semantic Scholar
An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.
C. Dutriaux, C. Robert, J. Grob, L. Mortier +14 more
2022European Journal of Cancer12 citations Open access
Semantic Scholar
LBA40 Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma
C. Lebbé, G. Long, C. Robert, O. Hamid +15 more
2022Annals of Oncology12 citations Open access
Semantic Scholar
Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction
Alexandra Landras, Coralie Reger de Moura, B. Villoutreix, M. Battistella +6 more
2022Oncogene11 citations
Semantic Scholar
Phase I study of Androgen deprivation therapy in combination with anti-PD-1 in patients pre- treated with anti-PD-1.
C. Robert, C. Lebbé, T. Lesimple, E. Lundström +6 more
2022Clinical Cancer Research11 citations Open access
Semantic Scholar
Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.
M. Girod, S. Dalle, L. Mortier, S. Dalac +14 more
2022JCO Precision Oncology11 citations
Semantic Scholar
Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy
M. Paillasse, Michael Esquerré, Florie Bertrand, celine Poussereau-Pomie +26 more
2022Cancer Research Communications11 citations Open access
Semantic Scholar
CD147 Promotes Tumor Lymphangiogenesis in Melanoma via PROX-1
Coralie Reger de Moura, Alexandra Landras, Farah Khayati, U. Maskos +5 more
2021Cancers11 citations Open access
Semantic Scholar
Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors.
M. Velev, B. Baroudjian, R. Pruvost, E. De Martin +25 more
2022European Journal of Cancer10 citations Open access
Semantic Scholar
Phase II study SECOMBIT (sequential combo immuno and target therapy study): A subgroup analysis with a longer follow-up.
P. Ascierto, M. Mandalà, P. Ferrucci, M. Guidoboni +16 more
2022Journal of Clinical Oncology10 citations
Semantic Scholar
Abstract LB198: A first-in-human, open-label, multicenter study of intratumoral SAR441000 (mixture of cytokine encoding mRNAs), as monotherapy and in combination with cemiplimab in patients with advanced solid tumors
O. Bechter, C. Loquai, S. Champiat, J. Baurain +19 more
2023Cancer Research9 citations Open access
Semantic Scholar
The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma
Marie-Léa Gauci, J. Giustiniani, C. Lepelletier, C. Garbar +6 more
2022Cancer Immunology and Immunotherapy9 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Grob×13
Invite
J. Grob — researcher profile on SciRah
P. Ascierto×11
Invite
P. Ascierto — researcher profile on SciRah
P. Saiag×10
Invite
P. Saiag — researcher profile on SciRah
A. Hauschild×8
Invite
A. Hauschild — researcher profile on SciRah

×8

Invite

M. Battistella — researcher profile on SciRah

Invite

C. Garbe — researcher profile on SciRah

V. del Marmol×7

Invite

V. del Marmol — researcher profile on SciRah

Invite

B. Dréno — researcher profile on SciRah

Invite

P. Lorigan — researcher profile on SciRah

Invite

R. Dummer — researcher profile on SciRah

Invite

T. Lesimple — researcher profile on SciRah

Invite

J. Delyon — researcher profile on SciRah